首页> 美国卫生研究院文献>Molecules >Elucidation of Vasodilation Response and Structure Activity Relationships of N2N4-Disubstituted Quinazoline 24-Diamines in a Rat Pulmonary Artery Model
【2h】

Elucidation of Vasodilation Response and Structure Activity Relationships of N2N4-Disubstituted Quinazoline 24-Diamines in a Rat Pulmonary Artery Model

机译:N2N4-二取代喹唑啉24-二胺在大鼠肺动脉模型中的血管舒张反应和结构活性关系的阐明

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Pulmonary arterial hypertension (PAH) is a rare and progressive disease arising from various etiologies and pathogenesis. PAH decreases life expectancy due to pulmonary vascular remodeling, elevation of mean pulmonary arterial pressure, and ultimately progresses to heart failure. While clinical treatments are available to reduce the associated symptoms, a complete cure has yet to be found. Phosphodiesterase-5 (PDE-5) inhibition has been identified as a possible intervention point in PAH treatment. The functional vasodilation response to N2,N4-diamino quinazoline analogues with differing PDE-5 inhibitory activities and varying physicochemical properties were assessed in both endothelium-intact and denuded rat pulmonary arteries to gain greater insight into their mode of action. All analogues produced vasorelaxant effects with EC50s ranging from 0.58 ± 0.22 µM to ˃30 µM. It was observed that vasodilation response in intact vessels was highly correlated with that of denuded vessels. The ~10% drop in activity is consistent with a loss of the nitric oxide mediated cyclic guanosine monophosphate (NO/cGMP) pathway in the latter case. A moderate correlation between the vasodilation response and PDE-5 inhibitory activity in the intact vessels was observed. Experimental protocol using the alpha-adrenergic (α1) receptor agonist, phenylephrine (PE), was undertaken to assess whether quinazoline derivatives showed competitive behavior similar to the α1 receptor blocker, prazosin, itself a quinazoline derivative, or to the PDE-5 inhibitor, sildenafil. Competitive experiments with the α1-adrenergic receptor agonist point to quinazoline derivatives under investigation here act via PDE-5 inhibition and not the former. The pre-incubation of pulmonary arterial rings with quinazoline test compounds (10 μM) reduced the contractile response to PE around 40–60%. The most promising compound (9) possessed ~32 folds higher selectivity in terms of vasodilation to its mammalian A549 cell cytotoxicity. This study provides experi0 0mental basis for PDE-5 inhibition as the mode of action for vasodilation by N2,N4-diamino quinazoline analogues along with their safety studies that may be beneficial in the treatment of various cardiovascular pathologies.
机译:肺动脉高压(PAH)是一种由各种病因和发病机制引起的罕见且进行性疾病。 PAH会由于肺血管重构,平均肺动脉压升高而降低预期寿命,并最终发展为心力衰竭。尽管临床治疗可减轻相关症状,但尚未找到完全治愈的方法。磷酸二酯酶5(PDE-5)抑制已被确定为PAH治疗的可能干预点。在内皮完好和裸露的大鼠肺内评估了对具有不同PDE-5抑制活性和不同理化性质的N 2 ,N 4 -二氨基喹唑啉类似物的功能性血管舒张反应动脉可以更深入地了解其作用方式。所有类似物均产生血管舒张作用,EC50为0.58±0.22 µM至to30 µM。观察到完整血管中的血管舒张反应与裸露的血管高度相关。在后一种情况下,活性降低约10%与一氧化氮介导的环鸟苷单磷酸(NO / cGMP)途径的丧失相一致。观察到血管扩张反应和完整血管中PDE-5抑制活性之间的适度相关性。进行了使用α-肾上腺素(α1)受体激动剂去氧肾上腺素(PE)的实验方案,以评估喹唑啉衍生物是否表现出与α1受体阻滞剂,吡唑嗪(本身为喹唑啉衍生物)或PDE-5抑制剂相似的竞争行为,西地那非。用α1-肾上腺素能受体激动剂进行的竞争性实验表明,所研究的喹唑啉衍生物是通过PDE-5抑制作用而不是前者抑制作用。肺动脉环与喹唑啉试验化合物(10μM)一起预孵育可将对PE的收缩反应降低约40–60%。就其哺乳动物A549细胞的细胞毒性而言,最有希望的化合物(9)在血管舒张方面具有约32倍的高选择性。这项研究为N 2 ,N 4 -二氨基喹唑啉类似物作为血管舒张作用的PDE-5抑制作用提供了实验依据,以及可能的安全性研究。对治疗各种心血管疾病有益。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号